Latest News for: Prv
Edit
NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 Is In Phase II Clinical Trials
ACCESSWIRE 29 Sep 2026
NV-387 for Measles would be eligible, upon approval, for receiving a Priority Review Voucher (PRV) from the US FDA as a benefit of the RPDD designation. A PRV can be sold and recent trades have fetched as much as $200 millionviii.
Edit
The Daily Record - Dunn
26 Sep 2026
PRV Tree Service Urges Austin TX Property Owners to Address Roof Clearance Before Branches Become Hazards
Just another WordPress site ....
- 1